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ABSTRACT
Autologous hematopoietic stem cell transplantation (auto HSCT) has become the standard treatment for
patients with relapsed diffuse large-cell non-Hodgkin’s lymphoma (NHL) responding to conventional salvage
chemotherapy. Nevertheless, more than half of these patients will relapse following auto HSCT and die. This
study was undertaken to determine whether the International Prognostic Index (IPI) assessed at time of
relapse (IPI-R) could be used to identify patients with greater probability for long-term survival following auto
HSCT. Eighty patients, median age 47 years (range 19-68 years), with diffuse large cell lymphoma in either
second complete remission (CR 2, n  27) or partial remission (PR 2, n  53) were treated between 1984 and
2002 with auto HSCT. Clinical features predictive of overall survival (OS) and progression-free survival (PFS)
were analyzed. Post-auto HSCT, CR was achieved in 73 patients (91%). With a median follow-up of 5 years
(range 1.0-14.2 years), OS and PFS at 5 years were 38% (95% confidence interval [CI] 27%-50%) and 32%
(95% CI 22%-42%), respectively. Two risk groups with significantly different OS and PFS were identified by
the IPI-R. The high-risk group (3, 4, or 5 IPI factors) had 2.0 times (95% CI 1.1-4.0, P  .03) the risk of death
and 2.2 times (95% CI 1.2-4.0, P  .01) the risk of relapse as the low-risk group (0, 1, or 2 IPI factors). The
median OS was 5 months versus 27 months and the median PFS was 2 months versus 8 months for the high-
and low-risk IPI-R groups, respectively. In Cox regression analysis, high-risk IPI-R status (relative risk [RR]
2.4, 95% CI 1.2-4.8, P  .02) and bone marrow (BM) involvement at diagnosis (RR 2.9, 95% CI 1.3-6.4, P 
.01) were independent predictors for poor OS. Similarly, high-risk IPI-R status (RR 2.5, 95% CI 1.3-4.7, P 
.01) and BM involvement at diagnosis (RR 3.9, 95% CI 1.7-8.7, P .001) were independent predictors for poor
PFS. These results suggest that the IPI-R predicts OS and PFS following auto HSCT for patients with
aggressive NHL in CR 2 or PR 2. Patients with high-risk IPI-R should be considered for novel therapeutic
approaches.
© 2007 American Society for Blood and Marrow Transplantation
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ﬁNTRODUCTION
Despite complete remission (CR) rates of 40% to
0% in response to anthracycline-based chemother- w
86py for diffuse large-cell non-Hodgkin’s lymphoma
NHL) [1,2], 30% to 50% of patients who achieve a
rst remission (CR1) will relapse [3]. Consolidation
ith autologous hematopoietic stem cell transplanta-
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IPI at Relapse and Auto HSCT Outcomes 487ion (auto HSCT) for patients in chemosensitive re-
apse was demonstrated by the PARMA trial to yield a
urvival advantage over conventional salvage chemo-
herapy [4]. However, over half of patients will relapse
ollowing transplantation.
The international prognostic index (IPI) has
ained wide acceptance as a model for predicting out-
omes in newly diagnosed aggressive lymphoma [5]. It
as developed as the result of an international con-
ortium that reviewed pretreatment clinical features of
ver 3000 patients with de novo diffuse aggressive
HL treated with a doxorubicin-containing chemo-
herapy regimen. The clinical features predictive of
elapse-free survival and overall survival (OS) included
ge, serum lactate dehydrogenase (LDH), perfor-
ance status (PS), stage, and extranodal involvement.
sum of the number of factors present placed patients
nto risk groups from which CR rate, 3-year relapse-
ree survival, and 3-year OS could be estimated. A
eparate model for younger patients, the age-adjusted
nternational index, resulted from limiting the sample
o patients 60 years of age or less; the risk factors that
emained independently signiﬁcant were tumor stage,
S, and LDH level [5].
Several studies have attempted to identify clinical
eatures that predict outcomes for patients with ag-
ressive lymphoma undergoing auto HSCT [6-13].
ndividual factors that have been associated with im-
roved survival following auto HSCT include dura-
ion of initial remission 12 months, minimal disease
tatus at auto HSCT, normal serum LDH, lack of
ulky disease, and ambulatory PS. Others have applied
odels such as the age-adjusted IPI to predict auto
SCT outcomes [10-12].
This study was undertaken to determine if the IPI
core assessed at time of relapse (IPI-R) predicts out-
omes of auto HSCT for patients with diffuse large-
ell NHL in second complete remission (CR 2) or
artial remission (PR 2).
ATIENTS AND METHODS
atient Characteristics and Criteria for Eligibility
Between October 1984 and December 2002, 80
onsecutive patients with diffuse large-cell lymphoma
n CR 2 (27 patients) or PR 2 (53 patients) underwent
uto HSCT at the University of Minnesota. All trans-
lants were performed under protocols approved by
he Human Subjects Committee of the University of
innesota. All subjects provided signed informed
onsent prior to transplantation.
Patients with a diagnosis of diffuse large-cell lym-
homa (according to the World Health Organization/
evised European-American Lymphoma system), in-
luding histologic subtypes of diffuse mixed-cell,
arge-cell immunoblastic, and anaplastic large cell, iere eligible for this study [14]. All available histology
pecimens obtained at diagnosis and at relapse were
eviewed. Patients who had transformed disease as
videnced by a prior diagnosis of follicular lymphoma
ere excluded. All patients underwent complete lab-
ratory, radiographic, and bone marrow (BM) evalu-
tion prior to transplantation. Patients were eligible
or transplantation according to research protocol cri-
eria at the University of Minnesota. These criteria
ncluded age 70 years, ECOG PS 1 (unless symp-
oms were attributed to lymphoma), creatinine 1.5
g/dL, or creatinine clearance 60 mL/min, total
ilirubin1.5 mg/dL, aspartate amino transferase and
lkaline phosphatase2 times the normal values, ejec-
ion fraction 45%, and carbon monoxide diffusing
apacity 50% of predicted.
Patients must have initially obtained a CR, as
eﬁned by the international working group to stan-
ardize response criteria for NHL, lasting at least 28
ays [15]. There were no restrictions on chemother-
py regimens or radiation therapy received at diagno-
is and at relapse. Disease burden at transplant could
e either CR 2 or PR 2. All refractory and chemore-
istant patients were excluded. Neither BM nor prior
uccessful treatment of central nervous system (CNS)
nvolvement was criteria for exclusion.
ata Collection
Baseline demographic data, pretransplantation char-
cteristics, transplantation protocol, response, toxicity,
nd survival were collected prospectively by the Bio-
tatistics Support Group at the University of Minne-
ota using standardized methods. This information
as supplemented by individual medical record re-
iews.
efinitions
Disease stage. Staging and disease bulk was based
n the Ann Arbor staging system [16]. Positron emis-
ion tomography imaging was not utilized for staging
urposes. Recorded sites of extranodal involvement
ncluded BM, gastrointestinal tract, liver, lung, CNS,
kin, testis, and bone.
IPI risk groups. The IPI-R was comprised of 5 risk
actors: age (60 versus60 years), stage (stage I or II
ersus stage III or IV), number of extranodal sites of
isease (1 versus 1), ECOG PS (0 or 1 versus 2),
nd serum LDH level (1 times normal versus 1
imes normal) [5]. For the purposes of this study, 2
isk groups were deﬁned: a low-risk group with 0, 1,
nd 2 IPI risk factors, and a high-risk group with 3, 4,
nd 5 IPI risk factors.
LDH values were available for 44 (55%) at re-
apse. Despite the missing LDH values, most patients
ould still be allocated into an IPI-risk group. For
nstance, a patient with no other adverse IPI factors
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R. E. Lerner et al.488ut with an unavailable LDH would remain in the
ow-IPI risk group, regardless of the LDH. In this
anner, the IPI-risk group was assigned for 98% of
atients at relapse. Two patients could not be assigned
n IPI-R risk group because of an unavailable LDH.
tatistical analysis was performed testing 3 scenarios:
he omission of these patients, the assumption of a
ormal LDH, and the assumption of an abnormal
DH. The analysis showed comparable results. The
ata presented in this paper represents the assumption
f an abnormal LDH.
Response criteria. Disease status was assessed imme-
iately prior to transplantation and then afterward at
ay 28 and day 100. Patients were subsequently re-
taged every 3 months in the ﬁrst year, every 6 months
or the second year, and yearly thereafter. A CR was
eﬁned as complete absence of disease on clinical,
adiographic, and pathologic evaluation. A PR was
eﬁned as a 50% reduction in the sum of the prod-
cts in greatest diameters of the 6 largest dominant
odes or nodal masses and no increase in the size of
he other nodes, liver, or spleen. A CR to transplan-
ation was deﬁned as resolution of disease-related ab-
ormalities on physical exam, imaging, and BM biopsy
t day 28. Minimal persistent imaging abnormalities
hat responded to a planned course of radiation ther-
py or that remained stable after a minimum of 4
eeks of follow-up were also included as CR. All other
esponses to transplantation were considered as per-
istent or progressive disease.
Treatment-related mortality (TRM). TRM was de-
ned as death occurring within 100 days of transplan-
ation not because of lymphoma.
uto HSCT Stem Cell Mobilization and
onditioning Regimens
Stem cell source and mobilization regimens were
etermined by BM status and protocol speciﬁcations
t the time of transplantation. Beginning in 1993,
atients were randomized to undergo either granulo-
yte colony stimulating factor (G-CSF) or granulocyte
acrophage colony stimulating factor (GM-CSF)
obilized BM (if free of disease) or peripheral blood
tem cells (PBSC). Beginning in 1995, PBSC priming
onsisted of 1 cycle of G-CSF 250 g/m2 subcutane-
usly for 4 consecutive days (days 1 to 4) followed by
pheresis collections (days 5 to 7). A second collection
ycle was preceded by priming chemotherapy with
ntravenous (i.v.) cyclophosphamide 4 g/m2 and cyt-
rabine 1 g/m2 twice daily on day 1, mitoxantrone 8
/m2 on days 1 and 2, and dexamethasone 20 mg/m2
wice daily for 4 doses on days 1 and 2 followed by
-CSF beginning on day 4 and continuing until com-
letion of aphereses. Patients who did not achieve the
inimum target of 2  106 CD34 cells/kg were
ligible to undergo GM-CSF mobilized BM harvest if
he BM was of adequate cellularity and free of disease. iConditioning regimens were assigned based on
rior radiotherapy and transplant protocol. The total
ody irradiation (TBI)-based conditioning regimen
ncluded cyclophosphamide 60 mg/kg IV daily for 2
ays (days 7 and 6), followed by fractionated TBI
65 cGy twice daily for 4 days (days 4, 3, 2, and
1) delivered at 5 to 10 cGy/min with a 10-MV linear
ccelerator. From 1983 to 1989, patients ineligible for
BI because of previous irradiation received i.v.
CNU (carmustine) 600 mg/m2 on day 6, cyclo-
hosphamide 50 mg/kg on days 5, 4, and 3, and
ytarabine 200 mg/m2 twice daily on days5,4, and
3. From 1989 forward, the chemotherapy-only con-
itioning regimen consisted of i.v. cyclophosphamide
.5 g/m2 for 4 days (days 6 to 3), BCNU 300
g/m2 day 6, and etoposide 150 mg/m2 twice daily
or 3 days (days 6 to 4). Prior to 1993, patients
n  6) received G-CSF for delayed neutrophil recov-
ry deﬁned as failure to achieve an absolute neutrophil
ount (ANC) of 200/L by day 28. Beginning in 1993,
ll patients (n  45) received G-CSF from day 0 until
ecovery of ANC to 2500/L for 2 consecutive days.
Patients with residual areas of limited disease at
valuation at day 28 after transplantation received
nvolved ﬁeld radiotherapy following transplantation.
upportive care and posttransplant follow-up evalua-
ions were according to institution protocol.
ndpoints
The primary endpoints for this study were OS and
FS. OS was measured from the day of stem cell
nfusion to death from any cause. PFS was measured
rom the day of stem cell infusion to documentation of
isease progression, relapse, or death from any cause.
n the absence of death or relapse, patients were cen-
ored at the time of last contact. Appraisal of trans-
lant response and TRM were secondary endpoints.
tatistical Methods
The clinical features at time of diagnosis, relapse,
nd transplantation that were evaluated for potential
rognostic importance included age, tumor stage, PS,
symptoms, sites of lymphoma involvement, number
f extranodal disease sites, BM involvement, disease
ulk, LDH; additional features included sex, initial
hemotherapy regimen, response to salvage chemo-
herapy, prior radiation therapy, duration of CR 1,
nterval between CR 1 and ﬁrst relapse, stem cell
ource, conditioning regimen, year of transplantation,
se of hematopoietic growth factors, and IPI-R. Vari-
bles that were independently predictive of OS and
FS with univariate analysis or were considered to be
f clinical relevance were tested in a multivariate
odel.
Comparisons of discrete variables were made us-
ng chi-square and Fisher’s exact tests, whereas com-
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IPI at Relapse and Auto HSCT Outcomes 489arisons of continuous variables were made with anal-
sis of variance (ANOVA). Probabilities of OS and
FS were calculated by using the Kaplan-Meier esti-
ation with 95% CI derived from standard errors [17].
ilcoxon tests were used to compare survival distribu-
ions [18]. Features independently associated with OS
nd PFS were identiﬁed in multivariate analyses by
ox proportional-hazards regression using forward-
tepwise model building [19]. SAS software, version
.1 (Cary, NC) was used for the statistical analysis.
ESULTS
escription of Patients and Treatment Outcomes
Eighty patients with diffuse large-cell lymphoma
ere analyzed in this study. Patient demographics and
linical characteristics not represented in the IPI are
able 1. Patient Demographics and Clinical Characteristics
Characteristic n (%)
ge at diagnosis
Median (range) years 47 (19-68)
Age >60 12 (15%)
ex
Male 46 (57%)
Female 34 (43%)
istologic subtypes
DLCL 53 (66%)
Diffuse mixed 11 (14%)
Immunoblastic 13 (16%)
Anaplastic 3 (4%)
one marrow
Involved at diagnosis 8 (10%)
symptoms
Present at diagnosis 20 (25%)
irst-line chemotherapy
Anthracycline-based 77 (96%)
CHOP 49 (61%)
uration of CR 1
>12 months 24 (30%)
esponse to salvage chemotherapy
CR 27 (34%)
PR 53 (66%)
ear of transplant
1984-1992 36 (45%)
1993-2002 44 (55%)
raft source
BM 41 (51%)
PBSC 36 (45%)
Both 3 (4%)
onditioning regimen
TBI-based 59 (74%)
Chemotherapy only 21 (26%)
rowth factor with transplant
None 29 (36%)
At day 0 45 (56%)
For delayed engraftment 6 (8%)
M indicates bone marrow; CHOP, cyclophosphamide, doxorubi-
cin, vincristine, and prednisone; CR, complete remission; CR 1,
ﬁrst complete remission; DLCL, diffuse large cell lymphoma;rPBSC, peripheral blood stem cell; TBI, total body irradiation.rovided in Table 1. The median age at diagnosis was
7 years (range 19-68 years) with 15% (n  12) of
he patients being older than 60 years. The majority of
he patients were male. At the time of transplantation,
7 patients (34%) were in CR 2 and 53 patients (66%)
ere in PR 2.
esponse to Auto HSCT and Survival
Seventy-three patients (91%) achieved a CR with
uto HSCT, 5 (6%) patients had persistent or pro-
ressive disease, and 2 (3%) died prior to day 28. Five
atients who received radiation for minimal residual
isease achieved CR; 3 remain in CR. Of the 31
atients (39%) who remain alive, 26 continue in CR at
median follow-up of 5 years (range 1.0-14.2 years).
he estimated 5-year OS and PFS are 38% (95%
onﬁdence interval [CI] 27-50%) and 32% (95% CI
2-42%), respectively.
rognostic Value of IPI Risk Group
The IPI-R risk factors are shown in Table 2. More
han 80% of patients were in the low-IPI risk group.
The IPI-R gave signiﬁcantly different Kaplan-
eier curves for the low-risk and high-risk groups
Figure 1). The median OS was 5 months versus 27
onths, and the median PFS was 2 months versus 8
onths for the high- and low-risk IPI-R groups, re-
pectively. The low- and high-IPI-R risk groups iden-
iﬁed patients with signiﬁcantly different probabilities
or OS and PFS (P  .01). The high-risk group had
.0 times (95% CI 1.1-4.0, P  .03) the risk of death
nd 2.2 times (95% CI 1.2-4.0, P  .01) the risk of
able 2. IPI Risk Factors at Relapse
Relapse
Characteristic N (%)
ge >60
Yes 12 (15%)
linical stage
I-II 42 (52%)
III-IV 38 (48%)
xtranodal sites >1
Yes 12 (15%)
S
0 or 1 64 (80%)
>2* 16 (20%)
DH abnormal
Yes 16 (20%)
No 28 (35%)
Unknown 36 (45%)
PI risk group
Low 68 (85%)
High 10 (13%)
Unknown 2 (2%)
PI indicates international prognostic index; LDH, lactate dehydro-
genase; PS, performance status.
PS 2 at transplant because of symptoms related to lymphoma.elapse as the low-risk group.
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R. E. Lerner et al.490The low- and high-risk IPI-R groups were com-
ared for differences in characteristics and prior treat-
ent that may confound transplant outcomes. Table 3
hows the comparison of clinical characteristics be-
ween the low- and high-risk IPI-R groups. Of the
actors that make up the IPI-R, age was the only
igure 1. Overall survival (a) and progression-free survival (b) by
PI-R (IPI at relapse) risk group.
able 3. Clinical Characteristics of Patients in Each IPI-R Risk
roup
Low Risk
0, 1, 2
Factors
(n  68)
High Risk
>3 Factors
(n  12)
Characteristic n (%) n (%) P-value
ge < 60 59 (87%) 4 (33%) .0001
ender: female 24 (35%) 7 (58%) .05
S: 0 or 1 62 (91%) 8 (80%) .07
tage: I or II 32 (47%) 6 (67%) .53
M involved 7 (10%) 1 (8%) .94
nitial chemo CHOP 35 (51%) 5 (42%) .73
R >12 mo 21 (31%) 2 (17%) .43
ransplant 1994-2002 33 (49%) 7 (58%) .26
tem cell source: PBSC 36 (53%) 3 (25%) .19
BI for conditioning 47 (69%) 8 (67%) .61
se of G-CSF 33 (49%) 7 (58%) .26
M indicates bone marrow; CHOP, cyclophosphamide, doxorubi-
cin, vincristine, and prednisone; CR, complete remission; G-
CSF, granulocyte-colony stimulating factor; IPI-R, interna-
tional prognostic index at relapse; PS, performance status;
PBSC, peripheral blood stem cell; TBI, total body irradiation. aharacteristic that was signiﬁcantly different between
he groups. There were no signiﬁcant differences be-
ween the IPI-R risk groups in regard to treatment
nd those variables that have been reported to inﬂu-
nce auto HSCT outcomes, such as chemotherapy,
uration of initial remission, and transplant source
6,9,13].
Under Cox regression, 2 variables, the IPI-R and
M involvement at diagnosis, remained predictive of
oth OS and PFS (Table 4). High-risk IPI-R was
ssociated with poor survival (relative risk [RR] of 2.4
5% CI 1.2-4.8, P  .02); BM involvement at diag-
osis (RR 2.9, 95% CI 1.3-6.4, p  .01) was also a
redictor for poor OS (Figure 2). Similarly, high-risk
PI-R status (RR 2.5, 95% CI 1.3-4.7, P  .01) and
M involvement at diagnosis (RR 3.9, 95% CI 1.7-
able 4. Multivariate Analysis of OS and PFS after Auto-HSCT
OS PFS
Factor RR (95% CI) P-value RR (95% CI) P-value
M involved at
diagnosis 2.9 (1.3-6.4) .01 3.9 (1.7-8.7) <.01
PI-R 2.4 (1.2-4.8) .02 2.5 (1.3-4.7) .01
M indicates bone marrow; IPI-R, international prognostic index at
time of relapse; PFS, progression-free survival; OS, overall sur-
vival; RR, relative risk; HSCT, hematopoietic stem cell trans-
plantation.
igure 2. Overall survival (a) and progression-free survival (b)
ccording to bone marrow involvement at diagnosis.
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IPI at Relapse and Auto HSCT Outcomes 491.7, P  .001) were independent predictors for poor
FS.
RM
Overall, 8 patients (10%) died prior to posttrans-
lant day 100. The 100 day TRM was 19% (7 deaths
n 36 patients) prior to 1993 but only 2% (1 death in
4 patients) for patients transplanted after 1993 (the
ear corresponding to incorporating both PBSC as a
raft source and the addition of G-CSF to posttrans-
lantation supportive care). The predominant cause of
RM was infection, followed by diffuse alveolar dam-
ge and/or hemorrhage, pulmonary embolism, and
ultisystem organ failure.
ISCUSSION
Several other groups have reported prognostic
ariables for auto HSCT outcomes; nevertheless, no
ingle index or set of variables has emerged as consis-
ently being predictive. Chemosensitivity, whether
ith primary refractory or relapsed disease, has been
hown to have an impact on transplantation outcomes
7,8,20-22]. Other studies have demonstrated the im-
act of conditioning regimens and graft source
23,24]. Because our hypothesis focused on IPI risk
roups, we designed our study population and end-
oints to be reﬂective of the initial international NHL
rognostic factors project. At the same time, in con-
rast to the PARMA [10], Hamlin et al [11], and
abbour et al [12] studies, we sought to extend the
pplicability of the IPI-R to a less restricted popula-
ion in age, types of chemotherapy regimens received,
onditioning regimens, and sites of disease involve-
ent.
The results of this study suggest that the IPI-R is
redictive of OS and PFS of auto HSCT in patients
ith diffuse large cell lymphoma in CR 2 or PR 2.
he IPI-R was able to identify 2 groups of patients
ith very different risks of death. The low-risk group,
ith a 5-year OS of 44%, has a reasonable long-term
urvival with auto HSCT. However, the high-risk
roup had a uniformly poor prognosis. By 18 months
osttransplant, 13 of 15 patients had relapsed and 12
f 15 had died.
Because of a relatively small overall sample size,
nknown LDH values, and a skewed distribution of
PI risk factors, the IPI was compressed into 2 risk
roups. The authors of the original IPI report sug-
ested dividing the IPI into risk groups when limited
y sample size and indeed conﬁrmed the predictive
alue of the groups with their patient sample [5]. The
ARMA [10], Hamlin et al [11], and Jabbour et al [12]
eports also utilized similar groupings. When the OS
nd PFS were estimated for each IPI risk level, there
as a large dropoff in survival between 0-2 factors and-4 factors, suggesting an appropriate cutoff point
etween the high- and low-risk groups.
There were no signiﬁcant differences, other than
ge and gender, between the 2 IPI-R risk groups in
egard to treatment and multiple baseline character-
stics. Gender has not been reported to inﬂuence
ransplant outcomes. Age, on the other hand, likely
lays a role in auto HSCT outcomes. Our study pop-
lation consisted of 15% patients 60 years old. This
s an important population to include given the rising
ncidence of NHL in the elderly [25]. Gopal et al [26]
emonstrated that auto HSCT can result in pro-
onged survival for patients over 60 years of age, al-
hough TRM is more signiﬁcant in these patients as
ell. In this study, age 60 years was signiﬁcant as a
ichotomous variable in univariate analysis but did not
emain signiﬁcant in multivariate analysis when added
o the IPI-R.
Multivariate analysis demonstrated that BM in-
olvement at diagnosis predicts for poor survival fol-
owing auto HSCT. BM involvement at relapse has
reviously been reported as a prognostic factor in a
odel proposed by Gugliemi et al [9]. In contrast, BM
nvolvement at relapse was not predictive of outcome
n the current study. It is important to emphasize that
ur analysis revealed that for patients with BM in-
olvement at diagnosis, outcomes of auto HSCT are
oor even in patients who maintain a negative BM
hrough relapse or achieve a negative BM prior to
uto HSCT.
In the report of auto HSCT for diffuse aggressive
HL in ﬁrst chemosensitive relapse or CR 2 from the
BMTR, the use of hematopoietic growth factors
G-CSF or GM-CSF) in recipients of BM grafts was
ssociated with an increased risk of disease progres-
ion [6]. However, no adverse effect of growth factors
as seen in this group of patients.
This study strongly suggests that the IPI-R is
redictive of outcomes in patients with chemosensi-
ive diffuse large-cell lymphoma in PR 2 or CR 2.
hese ﬁndings have signiﬁcance in aiding decision
aking at relapse. If a patient with diffuse large-cell
ymphoma falls into the unfavorable IPI group at the
ime of ﬁrst relapse, novel treatment strategies should
e considered, as outcomes with auto HSCT alone are
oor.
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